TK1 and neoplasm: Serum TK1 activity has been used to monitor the extent of tumour metastasis and prognosis in patients with acute leukaemia, chronic leukaemia, Hodgkin's and non-Hodgkin's lymphoma, bladder carcinoma, and cervical carcinoma (4–10).